Traditional Chinese Medicine Market is Driven by Rise in Popularity among Major Population from all Across the World
Global Traditional Chinese Medicine Market: Snapshot
In recent period, the major population from all across the world is inclined toward the use of traditional Chinese medicines. As a result, the traditional Chinese medicine market is experiencing notable expansion opportunities.
The traditional Chinese medicines are found to be helpful in protecting an individual’s cognitive health, maintaining their strength as well as flexibility. As a result, they are gaining popularity among major population from all across the world. This factor will drive the growth of the traditional Chinese medicine market in the years to come.
Request Brochure of Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=78855
TMR’s upcoming research report on the traditional Chinese medicine market focuses on providing in-depth study of diverse important factors shaping the future of this market. It includes study of challenges, drivers, restraints, and opportunities in the market for traditional Chinese medicine. Apart from this, the report delivers dependable data on shares, volume, and revenues of the market for traditional Chinese medicine. Thus, the report is a valuable handbook for all entities working in the traditional Chinese medicine market during the forecast period of 2020 to 2030.
The global traditional Chinese medicine market is segmented on the basis of various key factors such as product type, application, and region. Based on product type, the market for traditional Chinese medicine is bifurcated into Chinese herbal medicine and acupuncture and Tai Chi.
Global Traditional Chinese Medicine Market: Growth Dynamics
The traditional Chinese medicine market is witnessing prominent growth avenues on the back of increased acceptance from various developed and developing countries. The world is witnessing noteworthy growth in the number of older populace. This factor is pushing the market growth. This aside, the improved disposable income of major people in the world is expected to drive the growth of the traditional Chinese medicine market.
Growing urbanization, technological advancements in healthcare sector, and presence of favorable health insurance policies are some of the key factors stimulating the growth opportunities in the traditional Chinese medicine market. This aside, presence of favorable government policies will support the growth of the market for traditional Chinese medicine in the years ahead.
Request for Analysis of COVID-19 Impact on Traditional Chinese Medicine Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=78855
Global Traditional Chinese Medicine Market: Notable Development and Competitive Analysis
The traditional Chinese medicine market witnesses presence of gamut of players. As a result, the competitive landscape of the market for traditional Chinese medicine is highly intense. To sustain in this scenario, gamut of vendors working in this market are executing diverse strategies. Many players are growing their expenditure on research and development activities. This aside, many vendors are engaged in the launch of new products. All these activities connote that the traditional Chinese medicine market will experience remarkable growth in the upcoming years.
The list of key players in the traditional Chinese medicine market includes:
- Apicare Pain Clinic
- Tongrentang Hospital
- Beijing Chinese Medicine Hospital
- Dongzhimen Hospital
- Beijing Hua Kang Hospital
- Mayo Clinic
- YinOvaCenter and WOTCM
Pre Book Traditional Chinese Medicine Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=78855<ype=S
The notion that prisons can be sealed from the outside is “magical thinking.”
Nearly half of South Dakota’s 3,347-person prison population has tested positive for COVID-19, according to the most recent data released by the state’s department of corrections Tuesday.
“Unfortunately, the result was predictable,” said Leo Beletsky, a professor of law and health sciences at Northeastern University. “In many states, the top hotspots for COVID spread have been prisons and jails.”
South Dakota’s concerning rate of COVID-19 in prisons is part of a larger narrative. Like so many aspects of the pandemic, the virus has shined a light on vulnerable communities and weak spots in the health care system. Prisons and jails, many of which are chronically overcrowded dormitory settings with shared toilets and showers, and where basic hygiene is hard to uphold, are primed for infectious disease outbreaks.
“People don’t even have access to soap,” Beletsky added.
Then there’s the population itself. Incarcerated people have higher rates of underlying conditions than the general population, according to the Centers for Disease Control and Prevention, which puts them at risk for severe complications and death if they contract the virus.
“The reality is that people are living on top of each other and breathing infected air,” said Kate Chatfield, senior adviser for legislation and policy at The Justice Collaborative, a criminal justice research and advocacy organization.
In conjunction with the state health department, the corrections department is doing mass testing in all facilities, according to Mike Leidholt, secretary of corrections. In addition to screening for COVID-19 symptoms and quarantining those who test positive and their close contacts, they’ve restricted access to community work programs and suspended in-person visitation and volunteer opportunities.
In a statement to ABC News, Leidholt detailed additional changes, including: “revised schedules to increase social distancing, bolstered disinfection efforts and laundry services, implemented physical plant changes and adjusted admission and intake processes.”
“All inmates and staff are wearing masks,” Leidholt added.
Importantly, COVID-19 infections in South Dakota prisons don’t exist in a bubble. By every available metric, South Dakota’s COVID-19 outbreak is worsening. On Tuesday, daily infections, hospitalizations, testing positivity rate and deaths were all rising in South Dakota, according to an ABC News analysis of data from The COVID Tracking Project.
“This idea that a correctional facility can be cordoned off and sealed doesn’t reflect reality,” Beletsky said. “That’s magical thinking.”
Ionis’ third novel antisense medicine for ALS, its first designed to treat a broad ALS population, begins clinical trial
CARLSBAD, Calif., Oct. 22, 2020 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that the first patients have been dosed with ION541 (also known as BIIB105), an investigational antisense medicine being developed as a potential therapy to treat most forms of amyotrophic lateral sclerosis (ALS) regardless of family history. This is another milestone in the continuing progress of Ionis’ ambitious program to develop novel treatments for ALS. Almost all cases of ALS share the pathological hallmark of TDP-43 protein aggregation in motor neurons. ION541 targets ataxin-2 RNA (ATXN2), which has been shown to prevent or reverse TDP-43 toxicity in preclinical models of ALS.
ALS is a rare, progressive and fatal neurodegenerative disorder that affects approximately 55,000 people globally.i About 90 percent of ALS cases occur in people who have no apparent family history of the disease. People with ALS experience muscle weakness, loss of movement, and difficulty breathing and swallowing, resulting in a severely declining quality of life and potentially death.
“As our third medicine designed to treat different forms of ALS to enter clinical trials, ION541 represents yet another example of the power of Ionis’ antisense technology to potentially target root causes of devastating neurodegenerative diseases,” said Frank Bennett, Ph.D., Ionis’ chief scientific officer and franchise leader for neurological programs. “Initiation of this clinical trial for ION541 marks an important milestone in Ionis’ ALS program and reaffirms our commitment to the ALS community.”
Ionis received a payment of $10 million from Biogen for initiation of this Phase 1/2 clinical trial of ION541. Biogen is developing ION541 as part of a broad strategic collaboration with Ionis to advance novel antisense therapies for the treatment of neurological disorders.
Learn more about the Phase 1/2 trial of ION541 at: https://clinicaltrials.gov/ct2/show/NCT04494256?term=biib105&draw=2&rank=1
Ionis’ other leading investigational medicines to treat ALS are tofersen (BIIB067) and IONIS-C9Rx (BIIB078), both partnered with Biogen. Tofersen is designed to reduce the production of superoxide dismutase 1 (SOD1), the cause of a genetic form of ALS, referred to as SOD1-ALS, that results from mutations in the SOD1 gene. SOD1-ALS is the second most common genetic form of ALS, accounting for up to 20 percent of genetic ALS. Tofersen is currently in a Phase 3 clinical trial in SOD1-ALS patients with data expected in 2021. IONIS-C9Rx is designed to selectively reduce the mutant C9ORF72 RNA and associated neurotoxicity. Mutations in the C9orf72 gene account for greater than 30 percent of genetic ALS cases and five to 10 percent of all patients with ALS. It is the most common genetic form of ALS worldwide. IONIS-C9Rx is the first drug to enter clinical development that specifically targets the mutant C9ORF72 RNA and is a potentially first-in-class therapy for patients with C9orf72-ALS, referred to as C9-ALS. IONIS-C9Rx, which earlier this year received Fast Track designation from the U.S. Food and Drug Administration, is currently in a Phase 1/2 trial in C9-ALS patients.
Ionis’ Forward-looking Statement
This press release includes forward-looking
A nationwide study in France estimated that less than 5% of the population had coronavirus antibodies by mid-May.
The findings were posted ahead of peer review on Wednesday in medRxiv. Researchers from Public Health France, Department of Infectious Diseases, among others, said the study captures mild and asymptomatic cases that typically go unreported.
CLICK HERE FOR FULL CORONAVIRUS COVERAGE
Study authors estimated that, throughout the first wave of the epidemic, nationwide prevalence of antibodies climbed from 0.41% in March to nearly 5% by May, which translates to 3,292,000 infections, according to the study.
Also, about 70% of those with antibodies had detectable neutralizing antibodies, which varied across ages and regions, authors wrote.
Blood samples were analyzed from 11,021 people and then extrapolated to the nationwide population.
CORONAVIRUS ANTIBODIES PRESENT IN LESS THAN 10% OF AMERICANS, STUDY FINDS
“Seroprevalence estimates confirm that the nationwide lockdown substantially curbed transmission and that the vast majority of the French population remains susceptible to SARS-CoV-2 [the virus causing COVID-19 disease],” study authors wrote.
Antibody prevalence was highest in the area including Paris, where researchers noted the spread of infections happened earlier and more intensely.
“Our results are within the same order of magnitude as studies carried out at comparable epidemic stages in Europe,” the authors also wrote.
The study also found low infections among schoolchildren and suggested that the age group has restricted susceptibility and/or transmissibility.
“Our results provide a critical understanding of the progression of the first epidemic wave and provide a framework to inform the ongoing public health response as viral transmission is picking up again in France and globally,” they concluded. “Serological surveillance based on residual sera will continue to be used to provide timely seroprevalence estimates as the epidemic evolves and through the 2020-2021 winter season to monitor the progression of population-level immunity and guide public health response.”
CLICK HERE FOR THE FOX NEWS APP